Heft 6 / September 2015

  • Kommentar: Tamoxifen-Renaissance noch erfolgreicher durch Genotypisierung

Kommentar: Tamoxifen-Renaissance noch erfolgreicher durch Genotypisierung

J. Matthias Wenderlein

 

  1. Davis C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen-receptor-positive breast cancer: ATLAS, a randomized trial. The Lancet, online Dec 5th 2012http:/ /dx.doi.org/10.1016/SO140-6736(12)61963-1(ATLAS= The Adjuvant Tamoxifen – Longer Against Shorter).
  2. Karle J. et al. Influence of Cyp 2d6-genotype on Tamoxifen efficay in advanst Breastcancer in: Brest Cancer res Trieat (2013) 139: 553–560.
  3. Robert Koch–Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland (Hrsg).Krebs in Deutschland. Berlin 2013:9.
  4. Early Brest Cancer Trialists Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors of the efficacy of adjuvant tamoxifen: patient level metaanalysis of randomised trials Lancet 2011; 378 (9793):771–84.
  5. Regan MM et al. Cyp2D6 genotüpe and Tamoxifen response in postmenopausal in women with enocrine-rsponsive brest cancer: the breast international Group 1-98 trial. J. nat Cancer Inst 2012; 104 (6): 441–51.
  6. Province M.A et al. Clinical Pharmacology & Therapeutics CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-analysis of Heterogeneous Study Populations 2014; 95 2, 216–227. doi:10.1038/clpt.2013.186.
  7. Brauch H.et al. Tamoxifen Use in Postmenopausal Breast Cancer. CYP2D6 Matters. J Clin Oncol 2013;31:176–80(official journal of the American Society of Clinical Oncology).
  8. Kurian AW et al. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. JAMA 2014;312:902–14.
  9. Portschy PR et al. Survival Outcomes After Contralateral Prophylactic Mastectomy:A Decision Analysis.JNCI J Natl Cancer Inst 2014;106:doi:10.1093/jnci/dju160.
  10. Värri M et al.  Carotid intima-media thickness and calcification in relation to bone mineral density in postmenopausal women – the OSTPRE-BBA study Maturitas 2014;78(4):304–9.
  11. Fodor D et al: Relation between intima-media thickness and bone mineral density in postmenopausal women: a cross sectional study. Sao Paulo Med J. 2011;129(3):139–45+.
  12. Wenderlein J.M. Aromatasehemmer riskant für das Gehirn Geburtsh&Frauenheilk/Thieme-Verlag 2005; 65:144–148.
  13. Fauser F,  Wenderlein M. Antihormonelle Therapie bei Brustkrebs: Studien sprechen für Vorteile von Tamoxifen hinsichtlich des Risikos für ischämische Insulte.Frauenarzt 54 2013;10:990–993.
  14. Shilling V et al. The effects of oestrogens and anti-oestrogens on cognition. Breast 2001;484–91.
  15. Bender CM et al. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J. Pain Sympt Manag 2001; 21:407–24.
  16. Schilder CM et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial J Clin Oncol. 2010 ;28 (8): 1294–300.
  17. Janowsky JS. The role of androgens in cognition and brain aging in men. Neuroscience 2006; 138 (3):1015–20.
  18. Tchen M et al. Cognitive function, fatigue and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer J Clin Oncol. 2003;21:4175–83.
  19. Alibh S et al. Impact of Androgen Deprivation therapy on cognitive function in menwith nonmetastatic prostate cancer J Oncol 2010;28:5030–37.
  20. Pundole XN et al. Increase Incidence of Fractures in Recipients of Hematopoietic Stem-Cell Transplantation J. Clin Oncol 2015: online 14.3.; doi 10.1200/JCO.202457.8195.
  21. Michaelsson K et al: Long term calcium intake and rates of all cause and cardiovascular mortality BMJ 1013, 346:f228:doi:10.1136/bmj.f228.
  22. Cuzick J et al. Tamoxifen for prevention of breast cancer:extended longterm follow up of the IBIS-1 breast cancer prevention trial.Lancet Oncol 2015;16:67–75.
  23. Fisher B. et. al. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast Cancer Project Study in Natl Cancer J 90 1998; 1371–1388.
  24. O´ Farrell S et al. Risk and Timing of Cardiovascular Disease after Androgen-Deprivation Therapy in Men with Prostate Cancer. J Clin Oncol 2015: online 2.3. doi: 10.1200/JCO.2014.59.1792.
  25. Angermann C. Effects of selective serotonin re-uptake inhibition on mortality, morbidity and mood in depressed heart failure patients; American College of Cardiology 2015 Scientific Sessions; 16. März 2015; Abstract 414–05.
  26. Suppli NP et al. Increased Risk for Depression After Breast Cancer: A Nationwide Population-Based Cohort Study of Associated Factors in Denmark, 1998-2011. JCO 2014; online 27. Oktober; doi: 10.1200/JCO.2013.54.0419. 
  27. Timothy D. Predictors and Outcome of Heart Failure Complicating Type 2 Diabetes: The Fremantle Diabetes Study, 1490-P. Vorgestellt beim Kongress der American Diabetes Association 2015, 4.–9. Juni 2015, Boston. Cordero AM, Crider KS, Rogers LM, Cannon MJ, Berry RJ. Optimal serum and red blood cell folate concentrations in women of reproductive age for prevention of neural tube defects: world